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A whole range of complex interactions
develops between growing malignant
neoplastic cells and non-malignant stro-
mal elements of a tumour. The tumour
microenvironment includes a number
of interrelated elements: fibroblasts,
macrophages and dendritic cells, endo-
thelial cells, pericytes, inflammatory
cells and extracellular matrix compo-
nents. All these elements are actively in-
volved in tumour growth and progression
and angiogenesis, and can either pro-
mote or inhibit these processes. Un-
derstanding of the relationship between
the various components of the tumour
microenvironment and tumour cells
may allow the introduction of combi-
nation drug therapy having different tar-
get points which gives hope of reducing
the doses of medicines, and thus re-
ducing their toxicity while increasing
their efficiency.
Key words: tumour growth, microenvi-
ronment, macrophages, angiogenesis.
Wspolczesna Onkol (2011) vol. 15; (5) 305–308
The tumour and its microenvironment
– a complicated interplay
Magdalena Białas, Grzegorz Dyduch, Dariusz Adamek
Chair and Department of Pathomorphology, Jagiellonian University Medical College,
Krakow
Introduction
The emergence and growth of malignant tumour is a sequence of con-
secutive events which often lead to the development of multiple distant metas-
tases and the patient’s death. Tumour formation usually begins as a genet-
ic change in a single cell, such as mutation activating an oncogene or
deactivating a tumour suppressor gene. If the mutation is perpetuated, it in-
duces the proliferation of cells with new properties which are no longer sub-
ject to the body’s control system. The proliferation and spread of cancer cells
is closely linked to the effect of stromal elements, i.e. the tumour environment
in which it grows. Growing evidence suggests that the tumour microenvironment
is more than just a passive support structure for proliferating cancerous cells
and, in fact, plays a significant and active role in tumour progression. A bet-
ter understanding of mutual associations and interdependencies between the
cells of the growing tumour and elements of the tumour microenvironment
may contribute to the development of improved treatments for cancer patients.
Future cancer therapy will most likely be combination treatment based on con-
ventional chemotherapeutic agents possessing a direct cytotoxic effect
against tumour cells and substances targeted specifically against stromal el-
ements promoting tumour growth. 
Role of the microenvironment in tumour growth
Growing tumour tissue is a complex system incorporating a multitude of
relationships and loops between its various elements [1, 2]. Any attempt to
explore tumour biology only by investigating the properties of tumour cells
is an incomplete and inadequate approach which disregards the significant
influence of non-cancerous elements of the tumour’s immediate environment
on its growth and progression. The tumour microenvironment, i.e. connective
tissue and inflowing cells within which tumour grows, is a complex system
of different interconnected elements including:
• connective tissue fibroblasts,
• macrophages and dendritic cells,
• endothelial cells and pericytes,
• inflammatory infiltration cells,
• elements of the extracellular matrix.
All the elements are actively involved in tumour growth and progression
and may either promote or inhibit the processes enumerated above [1, 2]. 
Connective tissue fibroblasts
Fibroblasts are the most abundant cell population within the tumour mi-
croenvironment. Cancer associated fibroblasts (CAFs) may develop in the tu-
mour growth site either from preexisting fibroblasts or from mesenchymal stem
cells (STEM) from the marrow [2]. Cancer associated fibroblasts demonstrate
the expression of SMA (smooth muscle actin), i.e. acquire properties similar
to myofibroblasts, which play a central role in wound healing. Cancer asso-
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ciated fibroblasts are cells promoting tumour growth: they
stimulate the proliferation of cancer cells and facilitate tu-
mour progression, as well as being involved in the initiation
of invasion. Studies in mice showed that the blockade of the
PDGF (platelet-derived growth factor) receptor in stromal fi-
broblasts in cervical cancer delays cancer progression [3]. Med-
ications acting by inhibition of fibroblast activity may in the
future support conventional methods used in the treatment
of malignancies. 
Macrophages
Macrophages are cells derived from peripheral blood mono-
cytes, present in tissues. Macrophages have cytotoxic and
phagocytic properties and participate in inflammatory
processes. Macrophages presence outside blood vessels is
an effect of local secretion of chemotactic factors in the sur-
rounding tissue. The most important of them are M-CSF
(macrophage colony-stimulating factor), VEGF (vascular
endothelial growth factor), MCP-1 (monocyte chemotactic
protein) and angiopoietin [4, 5]. Under the influence of dif-
ferent signals from the tumour microenvironment, monocytes
migrating out of a vessel towards their target tissue site may
be differentiated either into M1 macrophages (classic
macrophage activation resulting in macrophages with pre-
dominantly anti-tumour activity) or M2 macrophages (al-
ternative activation mechanism producing macrophages with
pro-tumour activity) [5, 6]. Whether a monocyte is ultimately
transformed in the tissue into the M1 anti-tumoural
macrophage phenotype or the M2 pro-tumoural phenotype
depends on the type of stimulation induced by the tumour
microenvironment. 
Macrophages with the M1 phenotype develop as a result
of activation by selected cytokines, e.g. IFN-γ (interferon γ)
secreted during the inflammatory process and inducing clas-
sic monocyte/macrophage differentiation. Interferon  γ has
pro-inflammatory and anti-tumour activity, and the capac-
ity to eliminate pathogenic microorganisms. M1 macrophages:
• secrete pro-inflammatory cytokines: TNF (tumour necro-
sis factor), IL-1, IL-6 and IL-12 (interleukins 1, 6 and 12), thus
promoting inflammatory and anti-tumour responses,  
• have an enhanced capacity for generating active oxygen
forms, 
• exhibit potent cytotoxic properties: have the ability to de-
stroy tumour cells directly due to the so-called “antibody-
independent cytotoxicity” mechanism,
• have the capability of eliminating malignant cells via “an-
tibody-dependent cytotoxicity” (antibodies coat tumour cells,
while the macrophage binds to the Fc portion of the an-
tibody on the tumour cell). The process of tumour cell elim-
ination via this mechanism is much more efficient than the
previous one. Tumour cell destruction causes the release
of a range of antigens which are presented by antigen-
presenting cells (APCs) in the lymph nodes, which con-
tributes to tumour elimination. 
M2 phenotype macrophages (tumour associated
macrophages, TAMs) develop as a result of monocyte acti-
vation by cytokines, particularly those secreted by tumour
cells: IL-4 and IL-10 (interleukins 4 and 10). They mediate the
so-called alternative differentiation of monocytes into M2
phenotype macrophages. The cells possess anti-inflamma-
tory properties and cooperate with tumour cells, promoting
their growth. M2-type macrophages secrete a range of
chemokines and growth factors including PDGF (platelet-de-
rived growth factor), EGF (epidermal growth factor), TGF-β
(transforming growth factor β), M-CSF and IL8 [5-7]. 
Growth factors, especially PDGF and EGF secreted by M2
macrophages, stimulate tumour cells but, at the same time,
promote angiogenesis and the proliferation of pericytes around
new blood vessels. Pericytes stabilize the structure of new ves-
sels. Moreover, M2 macrophages produce VEGF-C, which plays
a part in stimulating proliferative processes.
M2 macrophages produce IL-10, a cytokine suppressing
and deregulating the cytotoxic activity of cytotoxic T-cells
(CD8+) and natural killer (NK) cells, reducing their anti-tu-
mour action [9]. Their distinctive feature is also the production
of proinflammatory cytokines (IL-1, IL-6, IL-12, TNF) in much
lower quantities in comparison with M1-type macrophages.
They also have a decreased capacity to generate active oxy-
gen forms. Other important properties of M2 macrophages
include production and secretion of substances degrading
elements of the extracellular matrix, chiefly matrix metal-
loproteinases 3 and 9 (MMP3 and MMP9) and the plas-
minogen activator, which can promote tumour growth and
the development of metastases.
The final activity of M2 macrophages depends on the mod-
ulatory effect of tumour cells. Epidermal growth factor-stim-
ulated tumour cells release M-CSF (CSF-1), which results in
continued differentiation of inflowing monocytes into
macrophages with the phenotype M2. The process further
stimulates tumour growth. Consequently, a specific loop de-
velops between M2 macrophages and tumour cells, inten-
sifying the activity of both cell types.  
A crucial factor determining the ultimate effect in the tis-
sue is the M1/M2 macrophage ratio; however, the majority
of macrophages within the tumour tissue assume pheno-
type M2. For some tumour types, an association was es-
tablished between increased percentages of M2 cells (TAMs)
in the tumour tissue and shorter patient survival times. 
It is also possible that macrophages infiltrating the tumour
can be a part of the tumour’s active strategy of avoiding the
immune response. As shown in our studies, macrophages of
this type demonstrate strong expression of the RCAS1 pro-
tein [10]. The protein, as studies by Sonoda et al. [11] sug-
gest, may play a major role in suppressing the immune re-
sponse targeted against the tumour. 
Endothelial cells and pericytes
For any tumour to grow to more than several millimetres
in diameter, it must create a new vascular network to ensure
appropriate supply of oxygen and nutrients to the neoplas-
tic tissue. The growth of new blood vessels, a process called
angiogenesis, is induced by the tumour’s pro-angiogenic fac-
tors including VEGF, angiopoietin 1 and 2 [12, 13], as well as
several other important factors: FGF-β (fibroblast growth fac-
tor β), TGF-β and IL-8 [14]. In normal physiological conditions
the above factors trigger angiogenesis at wound sites and
in regenerative processes [1]. New vessel creation also oc-
curs during embryogenesis [15]. In pathological conditions,
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besides tumour growth, angiogenesis is an important
mechanism in chronic inflammatory processes [2]. Angio-
genesis within the tumour tissue is a multi-step process in-
volving vascular endothelium, pericytes, smooth muscle cells
and inflowing inflammatory cells, as well as tumour stromal
elements [14]. VEGF-A, the most important pro-angiogenic
factor, acts via VEGFR1 and R2 receptors. The presence of 
VEGFR1 additionally stimulates the activity of metallopro-
teinases which may “loosen” the stroma, thus promoting vas-
cular growth, as well as producing a chemotactic effect on
monocytes and inducing their transformation into TAMs 
(M2-type tumour associated macrophages). Oxygen supply
to a specific tumour area is one of the factors determining
the type of monocyte activation and, consequently, the num-
ber of M2 macrophages in a particular area. M2 macrophages
are able to survive in poorly vascularized and oxygen-defi-
cient areas where they produce and secrete cytoki-nes (VEGF
and IL-8) and metalloproteinases (MMP-3 and MMP-9), which
induce and sustain angiogenesis and lymphangiogenesis 
[2, 5]. Similar action is performed by neutrophils, which also
have the ability to produce pro-angiogenic mediators [2]. It
is evident, then, that cells associated with the inflammato-
ry reaction not only fail to suppress the tumour but may even
promote its growth by stimulating the process of angio-
genesis.
Reduced blood and oxygen supply to tumour cells can slow
down neoplastic growth. Attempts are undertaken to interrupt
angiogenesis (i.e. new blood vessel growth within the tumour),
destroy existing vessels supplying the tumour and reduce
the concentration of pro-angiogenic factors within the tu-
mour. There are several substances available for clinical ap-
plication, including bevacizumab, a monoclonal antibody
against VEGF, or small-molecule inhibitors of tyrosine receptor
kinases such as sunitinib, sorafenib or pazopanib, whose anti-
tumour properties are associated, inter alia, with signal block-
ing via VEGF receptors [13]. Interferon α was also demon-
strated to suppress the activity of pro-angiogenic molecules
[16]. Anti-vascular action was also confirmed in TNF-α [17].
Drugs inhibiting angiogenesis and lymphangiogenesis, as
well as anti-vascular agents, are expected to become a use-
ful adjunct to existing conventional cancer treatments. 
Inflammatory infiltration cells
Not so long ago, the presence of inflammatory infiltration
within and around the tumour site was believed to be a man-
ifestation of the body’s defence against cancer, and as such,
a good prognostic indicator. It turned out, however, that the
lymphocyte response against the growing tumour is too weak
and insufficient to stop tumour growth in the majority of cas-
es. Evidence is mounting that developing tumours are in fact
able to use inflammatory cells to promote their own
growth. Rapid tumour expansion may lead to the develop-
ment of necrotic foci within the tumour site. In response to
that process, tumour and stromal cells adjacent to necrot-
ic areas may liberate cytokines which exert a chemotactic
influence on monocytes and granulocytes (GM-CSF) and fac-
tors stimulating tumour growth and angiogenesis, i.e.
VEGF, FGF-β, TNF and EGF [2]. Inflammatory cells accumu-
lating in the tumour’s vicinity support the inflammatory
process and secrete cytokines and growth factors promot-
ing the process of angiogenesis [4]. Inflowing neutrophils and
macrophages are the main sources of metalloproteinases
(MMP3 and 9) which degrade the tumour stroma and, con-
sequently, facilitate local tumour spread [2]. Eosinophils, cells
which are often present in small numbers among other cells
of the inflammatory infiltration, are also implicated in the
pro-angiogenic mechanism because of their ability to secrete
FGF-β, IL-6 and TGF-β. 
Elements of the extracellular matrix
Extracellular matrix elements, i.e. proteoglycans, glyco-
saminoglycans and type-I collagen, are a basis for all other com-
ponents of the tumour microenvironment and for multiplying
tumour cells. They also play an important role in facilitating
the diffusion of various substances, drugs in particular, with-
in the tumour site [18]. Loosening of the extracellular matrix
structure by enzymatic digestion may be a factor precipitat-
ing the distribution of anti-neoplastic agents; on the other hand,
it may contribute to the process of angiogenesis within the
tumour and to the initiation of tumour cell migration. Enzymes
involved in the degradation of the extracellular matrix are stro-
mal metalloproteinases, especially MMP3 and MMP9. They
are secreted, among others, by excited M2 macrophages. They
cause degradation of the basement membrane and promote
monocyte migration, as well as supporting angiogenesis. Uroki-
nase plasminogen activator [19] is also importantly implicat-
ed in the formation of metastases.
Summary
The tumour environment comprises multiple intercon-
nected elements which may either promote or suppress neo-
plastic development. Tumour cells modify the functions of
non-tumour elements of the tumour microenvironment: en-
dothelial cells, pericytes, fibroblasts, dendritic cells and in-
flammatory infiltration cells, macrophages in particular, thus
creating favourable conditions for tumour growth. At the
same time, modified cells of the microenvironment promote
neoplastic growth, tumour infiltration of surrounding tissues
and the development of metastases. Therefore, gaining bet-
ter insight into the tumour microenvironment and mutual
relations existing between its elements and tumour cells
seems to be an important step towards better understanding
of tumour biology. Recognition of these complicated rela-
tionships between different elements of the tumour mi-
croenvironment and neoplastic cells may potentially con-
tribute to the introduction of combination therapy with drugs
targeting various constituents of the tumour tissue. Such
treatment gives hope for reducing anti-tumour drug dos-
es, and thus lowering toxic effects, while increasing ther-
apeutic efficacy.
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